HEPLISAV™ efficacy in the Hep B #vaccine field

In R&D, Therapeutic Vaccines by Marcia ArdilaLeave a Comment

Dr J Tyler Martin, President, CMO & Director, DynaVax joined us a few weeks ago at the 12th annual World Vaccine Congress in Washington DC to discuss his views on HEPLISAVâ„¢ efficacy in the Hep B vaccine field.

Dr J Tyler Martin talked us through the unmet needs in Hepatitis B Vaccination:

    • Existing vaccines require ~6 months for protection
    5 -10% protected with first dose
    20 – 30% protected with 2nd dose of conventional vaccines
    • Reduced protection in patients with impaired immune responses
    ~67% protection in CKD, with 8 doses over 6 months
    • Lack of compliance with 3 dose regimen over 6 months (0,1 and 6 months)
    CDC statistics:  30% of subjects receive a 3rd dose

Some other key topics raised in his presentations:

•    Identifying the next steps after recent positive data demonstrating Heplisav's superior immune response
•    Planned Phase III registration trial and Phase III lot-to-lot consistency trial
•    What is on the horizon for US registration trials and European development strategies?

For the whole presentation and details on the above mentioned focus points, please download the presentation here.

Leave a Comment

Current ye@r *